SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
a paper boat that passes through obstacles and advances to its goal
Mergers & acquisitions
JPM26: Galapagos’ New CEO Is Here To Finally Turn the Ship Around
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil. 
January 19, 2026
 · 
4 min read
 · 
Annalee Armstrong
Job Trends
Bonus Episode: Q3 2025 Job Market Update
In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q4 job market performance and what it signals for 2026.
January 19, 2026
 · 
1 min read
 · 
Angela Gabriel
Vintage steam train with ancient locomotive and old carriages runs on the tracks in the countryside
IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced their IPOs this year. Meanwhile, Aktis Oncology began trading publicly earlier this month.
January 19, 2026
 · 
2 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
January 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hands holding arrow that goes up and down a few times and ends up in upward direction
Obesity
Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch
Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.
January 19, 2026
 · 
1 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH LOTTE BIOLOGICS
LOTTE Biologics Tightens Global Quality as Syracuse ADC Hub Ramps for 2026
With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.
January 19, 2026
 · 
2 min read
 · 
Jennifer C. Smith-Parker
Job Trends
Report: U.S. Life Sciences Job Market Report Q4 2025
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
January 19, 2026
 · 
1 min read
 · 
BioSpace Insights
Alzheimer’s memory loss due to Dementia and brain disease with the abstract medical icon of a human head and neurology research as a 3D illustration.
Alzheimer’s disease
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
January 19, 2026
 · 
7 min read
 · 
Ben Hargreaves
Organizing Solutions and organizer concept as a Management leadership taking charge as a leader sorting out diverse ropes into an organized patterns as a business concept for strategy and control.
FDA
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year
As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on clinical trial design and regulatory pathways to approval. Atara, meanwhile, lamented the agency’s “complete reversal of position” after its therapy for a rare surgical complication was rejected.
January 19, 2026
 · 
6 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS